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Abstract
Background: Host T-cell responses are associated with favorable outcomes in epithelial ovarian cancer (EOC), but it remains
unclear how best to promote these responses in patients. Toward this goal, we evaluated a panel of clinically relevant
cytokines for the ability to enhance multiple T-cell effector functions (polyfunctionality) in the native tumor environment.
Methodology/Principal Findings: Experiments were performed with resident CD8+ and CD4+ T cells in bulk ascites cell
preparations from high-grade serous EOC patients. T cells were stimulated with a-CD3 in the presence of 100% autologous
ascites fluid with or without exogenous IL-2, IL-12, IL-18 or IL-21, alone or in combination. T-cell proliferation (Ki-67) and
function (IFN-c, TNF-a, IL-2, CCL4, and CD107a expression) were assessed by multi-parameter flow cytometry. In parallel, 27
cytokines were measured in culture supernatants. While ascites fluid had variable effects on CD8+ and CD4+ T-cell
proliferation, it inhibited T-cell function in most patient samples, with CD107a, IFN-c, and CCL4 showing the greatest
inhibition. This was accompanied by reduced levels of IL-1b, IL-1ra, IL-9, IL-17, G-CSF, GM-CSF, Mip-1a, PDGF-bb, and bFGF in
culture supernatants. T-cell proliferation was enhanced by exogenous IL-2, but other T-cell functions were largely
unaffected by single cytokines. The combination of IL-2 with cytokines engaging complementary signaling pathways, in
particular IL-12 and IL-18, enhanced expression of IFN-c, TNF-a, and CCL4 in all patient samples by promoting polyfunctional
T-cell responses. Despite this, other functional parameters generally remained inhibited.
Conclusions/Significance: The EOC ascites environment disrupts multiple T-cell functions, and exogenous cytokines
engaging diverse signaling pathways only partially reverse these effects. Our results may explain the limited efficacy of
cytokine therapies for EOC to date. Full restoration of T-cell function will require activation of signaling pathways beyond
those engaged by IL-2, IL-12, IL-18, and IL-21.
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Introduction
Numerous studies in the past decade have shown that the
immune system influences clinical outcomes in patients with high-
grade serous epithelial ovarian cancer (hereafter referred to as
EOC). Specifically, the presence of tumor-infiltrating CD8+ T
cells is associated with prolonged disease-free and overall survival
[1,2]. Moreover, elevated numbers of CD56+ T cells in the ascites
compartment are correlated with increased platinum sensitivity
[3]. More recently, ascites fluid containing elevated levels of IL-17
(a cytokine predominately produced by Th17 and other effector T
cells [4]) was correlated with increased overall survival [5].
Together, these studies suggest that enhancing the endogenous T-
cell response to EOC may be of clinical benefit to patients.
However, the ovarian tumor environment contains many
immunosuppressive cell types and factors that can oppose anti-
tumor T-cell responses. Accordingly, elevated numbers of tumor-
associated regulatory T cells (Tregs) and macrophages are
associated with poor survival in EOC [1,2]. Many soluble
immunosuppressive factors are also found in ascites, including
IL-10, TGF-b, VEGF, B7-H1/PD-L1, B7-H4, SDF-1, EBAG9/
RCAS1, Fas ligand, and soluble IL-2 receptor [1,2].
The heterogeneity of immunosuppressive mechanisms in EOC
presents a formidable challenge for immunotherapy, as it suggests
that multiple immunosuppressive mechanisms might need to be
reversed to restore T-cell function. For example, Treg depletion is
being evaluated as a means to enhance immunity against several
human cancers [6], including EOC [7], but at best would only
reverse one mechanism of immunosuppression, leaving other
immunological barriers intact. Rather than attempt to disable these
barriers one by one, a more pragmatic clinical approach would be
to deliver factors that can broadly override immunosuppressive
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conditions that promote T-cell responses in the EOC environment
may lead to more effective immunotherapeutic strategies.
To this end, we previously developed a mouse model of EOC
that allows functional assessment of CD8+ T cell responses in the
ovarian tumor environment [8]. Specifically, we engineered a
murine EOC tumor line to express a CD8+ T cell epitope from
the model antigen ovalbumin. Mice bearing advanced, widely
disseminated tumors with extensive ascites were treated by
adoptive transfer of CD8+ T cells specific for the ovalbumin
epitope. Remarkably, adoptively transferred CD8+ T cells
underwent vigorous proliferation not only in lymph nodes and
peripheral blood, but also in the ascites and tumor compartments.
Indeed, at the peak of the response, the transferred T cells
constituted up to 40% of CD8+ T cells in peripheral blood, and up
to 96% of CD8+ T cells in ascites. This profound proliferative
response was followed by rapid and near-complete tumor
regression in the majority of animals, demonstrating that the T
cells were functionally active. Importantly, the proliferation and
anti-tumor activity of the transferred CD8+ T cells was entirely
dependent on IL-2/IL-15 signaling, as demonstrated by genetic
disruption of the IL-2 receptor alpha (CD25) or beta (CD122)
subunits [8]. Thus, even in the setting of advanced ovarian tumors,
CD8+ T cells mounted potent anti-tumor responses provided that
IL-2/IL-15 signaling pathways were intact.
The foregoing results raised the issue of whether cytokines such
as IL-2 can similarly over-ride the immunosuppressive effects of
ascites in human EOC. Previous in vitro studies with human EOC
samples have shown that IL-2 can partially restore lymphokine-
activated killer (LAK) cell cytotoxicity in the presence of 50%
ascites fluid, while the combination of IL-2 with TCR stimulation
[9] or IL-12 [10,11] fully restored LAK cytotoxicity. However, use
of 50% ascites fluid alone does not fully recapitulate the ovarian
tumor environment, which also contains immunosuppressive cell
types such as Tregs and MDSCs [1,2]. Furthermore, LAKs are
predominately comprised of NK cells, which may be affected
differently by ascites compared to T cells. In addition, these past
studies measured cytotoxicity by bulk LAK cell preparations and
hence did not elucidate the effects of cytokines on different T cell
subsets. Finally, in vitro cytotoxicity is only one aspect of T-cell
function and does not always correlate with effective T-cell
responses in vivo [12].
There is growing appreciation of the importance of polyfunc-
tional T-cells (i.e., T cells that can simultaneously perform multiple
functions) in effective immune responses [13]. Specifically,
polyfunctional T-cell responses are associated with protective
immunity after vaccination against smallpox (vaccinia virus) [14],
yellow fever [15], tuberculosis [16,17], and leishmaniasis [18].
Elevated numbers of polyfunctional T cells are also correlated with
favorable outcomes in a variety of disease settings, including HIV/
AIDS [19,20,21,22,23,24,25,26,27,28,29], hepatitis C [30], and
lymphocytic choriomeningitis [31]. In the setting of cancer, several
studies have found enhanced numbers of tumor-specific polyfunc-
tional T cells in patients responding favorably to various forms of
immunotherapy, including adoptive T-cell therapy, a-CTLA-4
antibody therapy, and tumor vaccines [32,33,34,35,36].
In the present study, we assessed for the first time the effects of
the human EOC ascites environment on T-cell polyfunctionality.
We also evaluated the ability of IL-2 and three other clinically
relevant cytokines (IL-12, IL-18, and IL-21) to restore a broad
range of T-cell functions. We found that ascites inhibited
polyfunctional responses by both CD4+ and CD8+ T cells, with
some functions showing greater inhibition than others. Further-
more, only a subset of T-cell functions was restored by exogenous
cytokines delivered alone or in combination. Thus, full restoration
of T-cell function in EOC will require activation of signaling
pathways beyond those engaged by IL-2, IL-12, IL-18, and IL-21.
Results
EOC ascites disrupts multiple T-cell functions
Primary ascites specimens were collected from patients with
high-grade serous EOC (Table 1). To model the native ascites
tumor environment as closely as possible in vitro, we analyzed bulk
ascites cell pellets, which in addition to CD8+ and CD4+ T cells,
contained resident tumor cells, Tregs, B cells, NK cells, and
CD14+ cells (Table 2). Moreover, cells were cultured in 100%
autologous ascites fluid to include any soluble factors, such as
TGF-b, IL-10, and VEGF (Table 2), that can impact T-cell
function. Because of the paucity of well-defined T-cell antigens in
ovarian cancer, we stimulated cultures with a-CD3 antibody,
which should stimulate both effector and regulatory subsets. Thus,
each patient’s T cells were analyzed in the presence of the full
complement of naturally occurring tumor cells, immunosuppres-
sive cells, and soluble factors.
We recently demonstrated in a murine model of EOC that the
ascites environment can be highly permissive to T-cell prolifera-
tion [8]. To see if this was also true in human EOC samples, we
tested the effect of ascites fluid on T-cell proliferation. As seen in
Fig. 1A, ascites fluid had highly variable effects on CD8+ T-cell
proliferation (as measured by Ki-67 expression), ranging from
strong inhibition (1/5 patients) to enhancement of proliferation (2/
5 patients). In general, similar trends were seen for CD4+ T cells
(data not shown). Thus, as suggested by our murine studies [8], the
human EOC ascites environment is not universally suppressive
and in some cases can enhance T-cell proliferation.
We next determined whether other T-cell functions were
similarly affected by ovarian ascites. Flow cytometric analysis was
Table 1. Patient clinical characteristics.
Patient ID Age at diagnosis Pathologic diagnosis Grade FIGO Staging TNM Staging
IROC008 70 Papillary serous carcinoma 3/3 4 pT3c, pN1
IROC028 61 Papillary serous carcinoma 3/3 3C pT3c, NX, MX
IROC034 64 Papillary serous carcinoma 3/3 N/A T3c
IROC036 60 Papillary serous carcinoma 3/3 N/A T3c, NX, MX
IROC038 40 Papillary serous carcinoma 3/3 3B pT3b
Median Age: 61; Mean Age: 59; Age Range: 40–70.
N/A, not assessed.
doi:10.1371/journal.pone.0015625.t001
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c, TNF-a, IL-2, CCL4, and CD107a [13,14,19,20,21]. The first
four markers are cytokines involved in T-cell proliferation or
effector function, whereas CD107a is expressed on the surface of T
cells undergoing cellular degranulation and thus serves as a marker
of cytotoxicity [13]. In 4/5 patient samples, ascites fluid caused a
dramatic inhibition of CD107a expression by CD8+ T cells
(Fig. 1A), which was accompanied by reduced levels of granzyme
B in culture supernatants (Supp. Fig. S1A), indicating the ascites
environment generally inhibits T-cell degranulation. CCL4 and
IFN-c expression were also inhibited by ascites in the majority of
patient samples (Fig. 1A). T cells expressing IL-2 and TNF-a were
relatively rare, and were minimally affected by ascites fluid in most
cases (Fig. 1A). Similar results were seen with CD4+ T cells (data
not shown). Intriguingly, the effects of ascites on T-cell
proliferation and other T-cell functions were largely uncoupled.
For example, with patient samples IROC008 and IROC036,
ascites fluid enhanced both CD8+ and CD4+ T-cell proliferation
but inhibited expression of CD107a, CCL4, and IFN-c (Fig. 1A,
and data not shown). Thus, ascites fluid has widely variable effects
on T-cell functions between patient samples, in accord with the
heterogeneous nature of EOC.
To further characterize the effects of ascites fluid on immune
function, culture supernatants from the above experiments were
evaluated by multiplex bead assays for expression of a broad panel
of cytokines associated with immunological and inflammatory
processes. Of 27 cytokines tested, nine (IL-1b, IL-1ra, IL-9, IL-17,
G-CSF, GM-CSF, Mip-1a, PDGF-bb, and bFGF) were inhibited
by ascites fluid compared to media in all 5 patient samples (Supp.
Fig. S1B). Ascites fluid had variable effects on the remaining
cytokines (data not shown). Although multiplex bead assays do not
provide information regarding the cellular source(s) of cytokines,
the results nonetheless underscore the broad effects of ascites fluid
on the cytokine milieu in EOC.
Although a systematic evaluation of the myriad immunosup-
pressive factors in EOC [1,2] was beyond the scope of this study,
we did investigate the possible influence of Tregs, TGF-b, IL-10,
and VEGF. The percentage of Tregs ranged from 2.5% to 6.8%
of total cells but showed no significant correlation with the degree
of inhibition of T-cell proliferation, or CD107a, CCL4, IFN-c,
TNF-a, and IL-2 expression; likewise, the levels of TGF-b, IL-10,
and VEGF in ascites fluid did not significantly correlate with the
degree of T-cell inhibition (Table 2; Pearson correlation p.0.05
for all comparisons). These findings underscore the complex
immunobiology of the ovarian tumor environment in that the
degree of immunosuppression did not correlate with these
common immunosuppressive factors.
Exogenous cytokines only partially restore T-cell function
in the EOC ascites environment
In our mouse model of EOC, IL-2/IL-15 signaling was critical
for CD8+ T-cell proliferation and function in ascites [8]. However,
the preceding experiments revealed that the vast majority of T
cells in EOC ascites did not express detectable levels of IL-2. This
led us to speculate that the addition of IL-2 to cultures might
restore T-cell proliferation and function. To test this, bulk ascites
cells were stimulated with a-CD3 in the presence of 100% ascites
fluid with or without exogenous IL-2, and T-cell proliferation and
function were measured 48 h later. In 4/5 patient samples, IL-2
fully reversed the effects of ascites on T-cell proliferation and
indeed induced responses greater than those seen in complete
media (Fig. 1B). By contrast, IL-2 had little effect on the expression
of CD107a, CCL4, IFN-c, or IL-2 for most patient samples,
although it caused a weak but statistically significant enhancement
of TNF-a expression (Fig. 1B). Thus, IL-2 alone enhanced T-cell
proliferation but, in general, had negligible effects on other
functions.
We next asked if the engagement of other signaling pathways
might better enhance T-cell function. Whereas IL-2 activates
primarily the STAT5 pathway, the related cytokine IL-12
activates the STAT4 pathway, which has been shown to enhance
T cell function in various physiological settings [37]. When added
to EOC cultures, IL-12 alone had only minor effects on the
proliferation or function of CD8+ T cells in most patient samples
(Fig. 1B). We next evaluated IL-21, which predominantly activates
the STAT1 and STAT3 pathways [38]. Similar to IL-12, IL-21
had only modest effects on T-cell proliferation or function (Fig. 1B).
In general, similar trends were seen with CD4+ T cells (data not
shown).
Reasoning that a broader degree of functional enhancement
might be achieved by simultaneously activating multiple STAT
pathways, we assessed two combinations of cytokines: a) IL-2+ IL-
12, and b) IL-2+ IL-12+ IL-21. Importantly, the latter combina-
tion would theoretically activate all STAT pathways relevant to
CD8+ T-cell responses (i.e., STAT1, STAT3, STAT4, and
STAT5). In general, both cytokine combinations induced T-cell
proliferation similar to that seen with IL-2 (compare Fig. 2 with
Fig. 1B). Notably however, CD8+ T cells from IROC028, which
failed to proliferate in response to any single cytokine (Fig. 1B),
proliferated in response to both cytokine combinations (Fig. 2).
Moreover, both cytokine combinations were modestly more
effective than single cytokines at enhancing IFN-c and TNF-a
production (Fig. 2). Despite this, neither cytokine combination
enhanced expression of CD107a or IL-2 (Fig. 2). Similar results
were seen with CD4+ T cells, although the effects of cytokines
Table 2. Cellular composition and TGF-b, IL-10, and VEGF
levels in the ascites compartment of EOC patients in this
study.
Parameter IROC Patient Sample
008 028
A 034 036 038
Lymphocytes
B 28.5 74.6 78.0 20.6 40.2
CD3+ 19.8 59.0 58.0 11.9 21.9
CD3+CD4+ 6.5 41.1 26.8 4.5 6.2
CD3+CD8+ 12.4 16.9 28.1 6.6 13.0
CD3+CD56+ 3.8 1.6 10.1 1.0 3.2




5.2 6.8 2.9 3.3 2.5
CD25+FoxP3+ in CD4+ 12.4 12.1 12.1 6.8 10.7
B cells
C (CD19+) 8.1 1.4 6.5 4.5 5.0
CD14+ 55.3 11.2 1.6 50.5 30.9
TGF-b (pg/ml) 6.3 ND
D 33.3 ND ND
IL-10 (pg/ml) 153.3 90.0 101.6 110.4 110.7
VEGF (pg/ml) 866.3 348.4 1304.4 2308.3 967.0
Cellular composition data is expressed as a percentage of total live cells.
Cytokine data is expressed using the indicated units.
ASample contained many large tumor rafts not detectable by FACS. Therefore,
values are inflated since visual inspection and IHC staining shows this sample
is comprised mainly of tumor cells.
BAs determined by side and forward scatter.
CTregs and B cells expressed as a percentage of total live lymphocytes.
DND, not detectable.
doi:10.1371/journal.pone.0015625.t002
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of cytokine combinations engaging a wide range of STAT
signaling pathways failed to fully restore T-cell function in the
EOC ascites environment.
Finally, we assessed whether activation of non-STAT signaling
pathways could further enhance T-cell function. To this end, we
evaluated the cytokine IL-18, which belongs to the IL-1 cytokine
family, activates the MyD88/NFkb pathway, and can directly
enhance CD8+ T-cell responses in a variety of settings [39,40,41].
IL-18 alone had weak effects on T-cell proliferation and function
(Fig. 3A). However, when combined with IL-2+ IL-12, IL-18
significantly enhanced expression of IFN-c and, to a lesser extent,
TNF-a (Fig. 3A). Moreover, the combination of IL-2+ IL-12+ IL-
18 significantly increased the amount of IFN-c produced on a per-
cell basis, as evidenced by increased mean fluorescence intensity
(MFI) (Fig. 3B, C). Nonetheless, the combination of IL-2+ IL-12+
IL-18 was unable to significantly enhance expression of CD107a
or IL-2 (Fig. 3A) and only modestly enhanced granzyme B release
(Supp. Fig. S2A). Likewise, this combination failed to restore
expression of IL-1b, IL-1ra, IL-9, IL-17, G-CSF, GM-CSF, Mip-
1a, PDGF-bb, or bFGF in culture supernatants (Supp. Fig. S2B).
This combination did, however, weakly increase the levels of IL-5
Figure 2. Effects of cytokine combinations on CD8+ T-cell proliferation and function. Bulk ascites cells were stimulated with plate bound
a-CD3 in media or 100% autologous ascites fluid for 48 h. Proliferation and function of CD8+ T cells in the presence of media, autologous ascites fluid
(top panel), or ascites fluid in the presence of IL-2+ IL-12 (middle panel), or IL-2+ IL-12+ IL-21 (bottom panel) was assessed by measuring expression of
Ki-67, CD107a, CCL4, IFN-c, TNF-a, and IL-2 by flow cytometry. Data has been normalized to a-CD3 stimulated cells in media (i.e., media values were
subtracted from each stimulation condition). *There was a significant effect of the cytokine combination for enhancing the indicated function
compared to cells stimulated in media (Wilcoxon matched pairs t test, p,0.05).
doi:10.1371/journal.pone.0015625.g002
Figure 1. Impact of ascites fluid and IL-2, IL-12, and IL-21 on CD8+ T-cell proliferation and function. Bulk ascites cells were stimulated
with plate bound a-CD3 in media or 100% autologous ascites fluid for 48 h. (A) Proliferation and function of CD8+ T cells in the presence of media or
autologous ascites fluid (top panel) was assessed by measuring expression of Ki-67, CD107a, CCL4, IFN-c, TNF-a, and IL-2 by flow cytometry. (B) Effect
of IL-2 (second panel), IL-12 (third panel), and IL-21 (fourth panel) on CD8+ T-cell proliferation and various functions in the presence of autologous
ascites fluid. Data has been normalized to a-CD3 stimulated cells in media (i.e., media values were subtracted from each stimulation condition).
*There was a significant effect of the cytokine for enhancing the indicated function compared to cells stimulated in media (Wilcoxon matched pairs t
test, p,0.05).
doi:10.1371/journal.pone.0015625.g001
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combination of IL-2+ IL-12+ IL-18 only partially restores T-cell
functionality in the EOC environment.
Exogenous cytokines induce new polyfunctional T-cell
profiles
In theory, the enhanced activity of cytokine combinations
compared to single cytokines could reflect either (a) different
cytokines stimulating distinct subpopulations of T cells, or (b)
cytokines acting synergistically to induce single T cells to perform
multiple functions (i.e., induction of polyfunctional T cells). To
investigate this issue, we used Boolean gate analysis to study the
different functional permutations displayed by CD8+ and CD4+ T
cells under different stimulation conditions. As seen in the top
panel of Fig. 4, when bulk ascites cells were stimulated in complete
media, only five predominant functional permutations were seen
among CD8+ T cells: (a) non-functional (i.e., zero function) T cells
(data not shown); (b) mono-functional T cells expressing CCL4 or
CD107a (permutations 2 and 5), (c) bi-functional T cells expressing
both CD107a and CCL4 (permutation 13), and (d) tri-functional T
cells expressing CD107a, CCL4, and IFN-c (permutation 24). In
the presence of 100% ascites fluid, the number of non-functional T
cells increased, whereas the other functional permutations were
reduced with the exception of mono-functional T cells expressing
CCL4 (Fig. 4, second panel). In general, addition of single
cytokines failed to significantly change the functional permutations
seen with ascites alone, although IL-2 had weak effects on several
permutations (Supp. Fig. S3). In contrast, the addition of cytokine
combinations (either IL-2+ IL-12+ IL-21, or IL-2+ IL-12+ IL-18)
markedly decreased the number of zero- and monofunctional T
cells and generated three new polyfunctional permutations: a)
CCL4 and IFN-c (permutation 10); b) CCL4, IFN-c, and TNF-a
(permutation 17); and c) CCL4, IFN-c, TNF-a, and CD107a
(permutation 28) (Fig. 4, third and fourth panels). Similar trends
were seen for CD4+ T cells, although the effects were generally
weaker (data not shown). Thus, these combinations of cytokines
appear to act synergistically to induce polyfunctional responses by
individual T cells as opposed to stimulating multiple subpopula-
tions of mono-functional T cells.
Discussion
We show here that the ascites environment in human EOC has
variable effects on CD8+ and CD4+ T-cell proliferation and
indeed can even enhance proliferation in some cases. By contrast,
ascites generally inhibits expression of IFN-c, TNF-a, CCL4, and
CD107a by T cells, resulting in a preponderance of zero- or
monofunctional T cells. Moreover, the ascites environment
generally inhibited expression of IL-1b, IL-1ra, IL-9, IL-17, G-
CSF, GM-CSF, Mip-1a, PDGF-bb, and bFGF in culture
supernatants. Although IL-2 could restore T-cell proliferation, it
was largely ineffective at enhancing other T-cell functions, as were
other single agent cytokines (IL-12, IL-18, and IL-21). Combina-
tions of cytokines that activate complementary signaling pathways
(in particular IL-2+ IL-12+ IL-18) were able to enhance expression
of IFN-c, TNF-a, and CCL4 but had negligible effects on other T-
cell functions. Thus, exogenous cytokines can partly restore T-cell
function in the human EOC environment; however, alternative
strategies will be required to fully restore T-cell function.
One limitation of this study is the relatively small sample size,
which was necessary given the number of cytokines and functional
read-outs involved. Despite the small sample size, there was a
notable degree of similarity between the overall functional profiles
of all five patient samples, both at baseline and after cytokine
stimulation. This suggests that the diverse immunosuppressive
mechanisms present in ovarian cancer might ultimately converge
toward a common T-cell functional state governed by a conserved
set of regulatory signals.
The release of cytotoxic granules is a major mechanism by
which T cells kill virus-infected and transformed cells [42]. We
found that ascites fluid strongly inhibited T cell degranulation, and
this was only partly restored by exogenous cytokines (as evidenced
by modest enhancement of granzyme B release). Previous studies
have shown that the combination of IL-2 with TCR stimulation
[9] or IL-12 [10,11] could fully restore LAK cytotoxicity in the
presence of 50% ascites fluid. This discrepancy with our results
may reflect the more demanding culture conditions we employed,
in that T cells were assayed in the presence of 100% ascites fluid
and a full complement of other tumor-associated cell types.
The lack of IL-2 production by both CD8+ and CD4+ T cells in
these experiments is also consistent with an impaired anti-tumor
response. In our mouse model of ovarian cancer [8], tumor
regression was entirely dependent on IL-2/IL-15 signaling.
Likewise, Gattinoni and colleagues demonstrated that effector
CD8+ T cells capable of potent in vitro anti-tumor cytotoxicity and
IFN-c production, but not IL-2 production, had limited anti-
tumor activity in vivo, whereas T cells that had low in vitro
cytotoxicity, but high IL-2 production, mediated superior anti-
tumor responses [12]. As CD8+ T cells generally lose the ability to
produce IL-2 upon differentiation, the failure of cytokines to
enhance IL-2 production suggests that most tumor-associated T
cells may be terminally differentiated effectors [13]. If so, future
efforts should be directed toward isolating and expanding less
differentiated subsets of T cells with greater pluripotency.
In addition to failed IL-2 production, we found that ascites fluid
inhibited the expression of numerous other cytokines (IL-1b, IL-
1ra, IL-9, IL-17, G-CSF, GM-CSF, Mip-1a, PDGF-bb, and
bFGF) in culture supernatants. Although the multiplex cytokine
assay we employed cannot discriminate which cell type(s) is
inhibited from producing these cytokines, many of these cytokines
have documented roles in T-cell responses and hence their
reduced levels are expected to impact T-cell function. In
particular, IL-17 is produced by the Th17 subset of CD4+ T
cells under inflammatory conditions and has been correlated with
improved overall survival in EOC [5]. Given that the combination
of IL-2+ IL-12+ IL-18 failed to enhance IL-17 production,
Figure 3. Effects of IL-18 alone, or in combination with IL-2 and IL-12, on CD8+ T-cell proliferation and function. Bulk ascites cells were
stimulated with plate bound a-CD3 in media or 100% autologous ascites fluid for 48 h. Proliferation and function of CD8+ T cells in the presence of
media or autologous ascites fluid (top panel) was assessed by measuring expression of Ki-67, CD107a, CCL4, IFN-c, TNF-a, and IL-2 by flow cytometry.
(A) Effect of IL-18 (middle panel) and IL-2+ IL-12+ IL-18 (bottom panel) on CD8+ T-cell proliferation and various functions in the presence of ascites
fluid. Data has been normalized to a-CD3 stimulated cells in media (i.e., media values were subtracted from each stimulation condition). *There was a
significant effect of IL-2+ IL-12+ IL-18 for enhancing the indicated function compared to cells stimulated in media (Wilcoxon matched pairs t test,
p,0.05). (B) Mean fluorescence intensity (MFI) of IFN-c positive CD8+ T cells was determined by intracellular IFN-c staining. *The effect of IL-2+ IL-12+
IL-18 was significantly greater than the other two cytokine combinations (Wilcoxon matched pairs t test, p,0.05). (C) Representative flow cytometry
plots demonstrating the effect of cytokine combinations on IFN-c production on a per-cell basis. Shown are the mean flourescence intensity (Y axis)
of IFN-c production and the percentage of CD8+ cells expressing IFN-c (numbers). All data are gated on CD8+ lymphocytes.
doi:10.1371/journal.pone.0015625.g003
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pathway within the tumor environment. For example, IL-1b, IL-6,
TGF-b, IL-23, and ICOS have all been shown to influence the
differentiation, expansion or function of Th17 cells [4,43], and
thus could potentially be manipulated to promote IL-17
production in vivo.
In contrast to these other cytokine defects, the combination of
IL-2+ IL-12+ IL-18 potently enhanced IFN-c production by
CD8+ T cells (Fig. 3B, C). IFN-c plays a central role in anti-tumor
immunity by inhibiting tumor proliferation and angiogenesis, and
upregulating tumor antigen presentation. Endogenous IFN-c
protects against tumor development and, in a number of tumor
models, is critical for anti-tumor immunity [44]. Moreover, IFN-c
and IFN-c receptor expression, as well as several genes
downstream of IFN-c, are associated with increased survival in
human EOC [1]. How might IL-2, IL-12, and IL-18 cooperatively
enhance IFN-c production? First, these cytokines reciprocally
upregulate expression of their respective receptors, resulting in
enhanced sensitivity of T cells to all three cytokines [45,46,47,48].
Second, these cytokines can mediate synergistic and complemen-
Figure 4. Effects of cytokine combinations on polyfunctional CD8+ T-cell responses. Bulk ascites cells were stimulated with plate bound a-
CD3 in media or 100% autologous ascites fluid for 48 h in the presence or absence of the indicated cytokine combination. Boolean gate analysis was
performed to quantify the number of T cells expressing each of 31 possible functional permutations. Shown are the results for CD8+ T cells
stimulated in media, ascites fluid, or ascites fluid supplemented with the cytokine combinations IL-2+ IL-12+ IL-21 or IL-2+ IL-12+ IL-18. The frequency
of T cells expressing a given permutation is expressed as a percentage of total CD8+ T cells. *For the indicated permutation, the effect of the cytokine
combination was significantly greater than that seen with media (Wilcoxon matched pairs t test, p,0.05).
doi:10.1371/journal.pone.0015625.g004
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synergistically activate the p38 MAPK pathway to enhance IFN-c
expression [51]. Likewise, IL-12 and IL-18 activate the transcrip-
tion factors STAT4 and AP-1, respectively, which can synergis-
tically enhance IFN-c promoter activity [52]. Thus, the coordi-
nated activation of both STAT and non-STAT signaling pathways
appears important for maximal expression of IFN-c.I ti s
noteworthy, however, that these signals were not sufficient to
restore expression of many other cytokines. This suggests that, in
future, cytokines other than IFN-c should be used as read-outs if
one wishes to optimize the full range of T cell functions for cancer
immunotherapy.
The combination of IL-2+ IL-12+ IL-18 also induced significant
changes in polyfunctional T-cell permutations. Although the
clinical significance of these polyfunctional profiles has yet to be
determined for EOC, insights can be gained from other disease
settings. Two of the four functional permutations seen at baseline
(specifically, monofunctional CD107a, and bi-functional CD107a
and CCL4; Fig. 4) are also elevated in CD8+ T cells from HIV
progressors compared to non-progressors, suggesting that these
permutations may represent functionally exhausted T cells
[19,20]. Addition of IL-2+ IL-12+ IL-18 decreased the number
of CD8+ T cells exhibiting these ‘‘exhausted’’ functional
permutations. Moreover, it caused the emergence of three new
polyfunctional permutations: a) CCL4 and IFN-c; b) CCL4, IFN-
c, and TNF-a; and c) CCL4, IFN-c, TNF-a, and CD107a (Fig. 4).
Notably, these three permutations were shown to be induced in
CD8+ T cells by a protective vaccine against smallpox [14].
Furthermore, tetra-functional (CCL4, IFN-c, TNF-a, and
CD107a) CD8+ T cells are found at significantly higher
frequencies in HIV long-term non-progressors compared to
progressors [19,20]. Finally, higher proportions of tumor-reactive
T cells co-expressing CCL4, IFN-c, and TNF-a were detected in
melanoma patients with favorable clinical responses to a-CTLA-4
treatment [34]. These prior reports suggest that the polyfunctional
permutations induced by IL-2+ IL-12+ IL-18 may have
therapeutic benefit in EOC, although this suggestion needs to be
validated in vivo.
Our findings shed new light on previous clinical trials in EOC
involving IL-2 and IL-12. Intraperitoneal administration of IL-2
resulted in an approximately 25% overall response rate in two studies
[53,54], while IL-2 in combination with retinoic acid as a
maintenance therapy demonstrated a relatively modest, but statisti-
cally significant, prolongation of progression-free and overall survival
in a phase II trial [55,56]. By contrast, IL-12 has shown little
therapeutic efficacy in EOC in two clinical trials [57,58]. The limited
efficacy of IL-2 and IL-12 as monotherapies is consistent with our
resultsdemonstrating the modest functional activityofthesecytokines
as single agents. Our results would also predict that IL-18 and IL-21
may have limited clinical efficacy when used as monotherapies.
Indeed, although IL-18 and IL-21 have not been evaluated in EOC
patients, these cytokines as single agents showed limited clinical
benefit in the setting of metastatic melanoma [59,60,61,62,63,64].
When combined, IL-2, IL-12, and IL-18 showed the most promise in
the in vitro experiments reported here, but unfortunately these
cytokines would likely have significant side effects if given in
combination to patients [47,65,66]. While it may be possible to
reduce toxicity by optimizing dose and route of delivery (e.g.,
intraperitoneal administration) [47,67], one is still left with the fact
that this combination does not fully restore T-cell function, as
manifested by impaired expression of CD107a, IL-2, and other
cytokines. Thus, our findings indicate that alternative therapeutic
strategies involving other signaling pathways will be required to
unleash the full potential of host T-cell responses against EOC.
Materials and Methods
Study subjects and specimens
Ethics Statement. Newly diagnosed patients with high-grade
serous EOC gave written informed consent under protocols
approved by the Research Ethics Board of the BC Cancer Agency
and the University of British Columbia.
Tumor tissue and ascites were obtained during primary surgery
prior to any other treatment. Ascites was centrifuged at 300 g, and
supernatants (ascites fluid) were stored at 280uC. Ascites cell (AC)
pellets containing large quantities of red blood cells were treated
with ACK lysis buffer. AC pellets were cryopreserved in liquid
nitrogen. Upon thawing, ascites cells were rested in complete
RPMI (RPMI 1640 with 10% FBS, 25 mM HEPES, 1 mM
sodium pyruvate, 2 mM L-glutamine, and 50 mm b-mercaptoeth-
anol) for 4 h at 37uC prior to experiments.
Antibodies, cytokines, and ELISAs
Flow cytometry was performed with the following fluorochrome-
conjugated antibodies (BD Biosciences): CD3 (FITC, PECy5), CD4
(FITC, PE), CD8 (PECy5, APC-H7), CD14 (PE), CD19 (PE),
CD25 (PECy5), CD56 (PE), CD107a (PECy5), Ki-67 (FITC),
CCL4 (Mip-1b, PE), IL-2 (APC), TNF-a (PECy7), and IFN-c (PE,
AlexaFluor 700). Foxp3 (PE) was from eBioscience. Recombinant
human IL-12, IL-21 (both from Peprotech), and IL-18 (R&D
Systems) were used at 100 ng/ml. IL-2 (Proleukin) was used at
100 U/ml. ELISA was used to measure TGF-b (latent and active;
eBioscience) and granzyme B (Mabtech) in ascites fluid, according
to manufacturers’ instructions.
Proliferation assays
Ascites cells (AC) were seeded in triplicate in 96-well flat bottom
plates at 1610
5 cells per well. AC were resuspended in media or
100% ascites fluid and were left unstimulated or stimulated with
plate bound a-CD3e antibody (clone OKT3, eBioscience)
previously coated at 2.5 mg/ml for 2 h at 37uC. Cells were
stimulated for 48 h in the presence or absence of cytokines, and T-
cell proliferation was measured by detection of Ki-67 using flow
cytometry. Cells were washed with FACS buffer (1% FBS in PBS),
permeabilized with ice-cold 100% methanol and incubated at
220uC for at least 1 h. Cells were then washed with FACS buffer
and triple-stained with pre-titered antibodies to Ki-67, CD4, and
CD8 for at least 30 min at room temperature in the dark. Cells
were washed and analyzed with a FACSCalibur flow cytometer
(Becton Dickinson). Data was analyzed using FlowJo software
(Tree Star Inc.).
Assessment of T-cell functional markers
Bulk ascites cells were washed with serum-free RPMI,
resuspended at 5610
5 cells/ml in complete RPMI or autologous
ascites fluid, and plated in 48-well plates at 3610
5 cells/well with
or without plate bound a-CD3e. Cytokines and a-CD107a
antibody were added to appropriate wells, and cells were
incubated for 48 h at 37uC. As per standard protocol, a-
CD107a antibody was added during stimulation because
CD107a, which is associated with the membranes of cytotoxic
granules, transiently localizes to the surface of T cells undergoing
cellular degranulation [68]. Thus, cell-surface expression of
CD107a serves as a surrogate marker of cytotoxicity. As a positive
control, PMA plus ionomycin (both from Sigma) were used at
40 ng/ml and 1.5 mg/ml, respectively. GolgiStop (BD Bioscience,
1:1500 dilution) and brefeldinA (Sigma, 5 mg/ml) were added for
the final 6 h of culture. Cells were harvested, labeled with a-CD4
and CD8 antibodies, fixed and permeabilized with Cytofix/
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instructions, washed with Perm/Wash buffer, and stored in FACS
buffer overnight at 4uC. Cells were washed again with Perm/
Wash buffer, and intracellular staining was performed using
antibodies against CCL4, IL-2, TNF-a, and IFN-c. Cells were
fixed with 2% formaldehyde and stored in FACS buffer overnight
at 4uC. Samples were analyzed with a BD Bioscience FACSVan-
tage DIVA modified with the Octagon array. SSC Area vs. SSC
W were used to gate out doublets. Data was analyzed with FlowJo
software (TreeStar) and exported to PESTLE v1.6.1 (Mario
Roederer, NIH) for further data analysis.
Multiplex cytokine assays
Supernatants harvested from cultures described in ‘‘Prolifera-
tion assays’’ were assessed for expression of 27 cytokines using the
Bio-Plex human cytokine 27-plex panel (Bio-Rad) according to
manufacturer’s recommended protocol. The evaluated cytokines
included interleukins-1b, -1ra, -2, -4, -5, -6, -7, -8, -9, -10, -12
(p70), -13, -15, and -17, and basic FGF, eotaxin, G-CSF, GM-
CSF, IFN-c, IP-10, MCP-1, CCL3/Mip-1a, CCL4, PDGF-BB,
RANTES, TNF-a, and VEGF.
Supporting Information
Figure S1 Impact of ascites fluid on granzyme B and
cytokine expression. Bulk ascites cells were stimulated for 48 h
with plate bound a-CD3 in media or 100% autologous ascites
fluid. The expression of (A) granzyme B, and (B) 27 cytokines was
assessed in culture supernatants using ELISA and multiplex
cytokine assays, respectively. Data is shown for all a-CD3-induced
cytokines that were significantly impaired by ascites fluid
(Wilcoxon matched pairs t test, p,0.05). * Indicates maximum
discernible concentration; actual value may exceed this value.
(EPS)
Figure S2 Effects of the cytokine combination of IL-2+
IL-12+ IL-18 on granzyme B and cytokine expression.
Bulk ascites cells were stimulated for 48 h with plate bound a-CD3
in media or 100% autologous ascites fluid in the absence or
presence of IL-2+ IL-12+ IL-18. The expression of (A) granzyme
B, and (B) the indicated cytokines was assessed in culture
supernatants using ELISA and multiplex cytokine assays, respec-
tively. Data was normalized to a-CD3 stimulated cells in media by
calculating the % change using the following equation: (B – A)/A,
where B is the measured value in the indicated condition and A is
the measured value in media. * IL-2+ IL-12+ IL-18 significantly
enhanced the indicated function compared to cells stimulated in
ascites fluid alone (Wilcoxon matched pairs t test, p,0.05).
(EPS)
Figure S3 Effects of IL-2, IL-12, IL-18, and IL-21 on
polyfunctional CD8+ T-cell responses. Bulk ascites cells
were stimulated with plate bound a-CD3 in media or 100%
autologous ascites fluid for 48 h in the presence or absence of the
indicated cytokine. Boolean gate analysis was performed to
quantify the number of T cells expressing each of 31 possible
functional permutations. Shown are the results for CD8+ T cells
stimulated in ascites fluid in the presence of IL-2, IL-12, IL-18, or
IL-21. The frequency of T cells expressing a given permutation is
expressed as a percentage of total CD8+ T cells. *For the indicated
permutation, the effect of the cytokine was significantly greater
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